Table 2. Patient Demographics, Tumor Stage, Alterations in the EGFR Signaling Pathway and Survival in Patients with Pancreatobiliary- and Intestinal-Type Ampullary Adenocarcinoma.
| Intestinal (n=25) | Pancreatobiliary (N=24)* |
P Value | ||
|---|---|---|---|---|
| Age (years) | 60 (50 – 65) | 69 (62 – 74) | 0.028* | |
| Sex | 0.3772 | |||
| Female | 44% (11) | 29% ( 7) | ||
| Male | 56% (14) | 71% (17) | ||
| Tumor stage | 0.0082 | |||
| I | 46% (11) | 9% ( 2) | ||
| II-III | 54% (13) | 91% (21) | ||
|
AR immunohistochemstry
score |
8 (3 – 12) | 5 (2 – 12) | 0.696* | |
| EGFR | 0.0022 | |||
| Positive | 4% ( 1) | 42% (10) | ||
| Negative | 96% (24) | 58% (14) | ||
| pEGFR | 0.0022 | |||
| Positive | 0% ( 0) | 33% ( 8) | ||
| Negative | 100% (25) | 67% (16) | ||
| Gene mutation | 0.2232 | |||
| KRAS codons 12 and 13 | 52% (13) | 29% ( 7) | ||
| Other mutation | 8% ( 2) | 21% ( 5) | ||
| No mutation | 40% (10) | 50% (12) | ||
| Overall survival status | 0.0212 | |||
| Alive | 60% (15) | 25% ( 6) | ||
| Dead | 40% (10) | 75% (18) | ||
| Follow up time (months) | 52 (29 – 83) | 27 (14– 69) | 0.0931 | |
*
:Median (interquartile range) for continuous variables and N (%) for categorical variables
1
:Wilcoxon test
2
:Fisher’s exact test
Abbreviations: EGFR - epidermal growth factor receptor; AR - amphiregulin; pEGFR - phosphor-EGFR